Syntax Research’s Moderna MRNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.5K Buy
+13
New +$1.4K ﹤0.01% 178
2025
Q3
– Sell
-100
Closed -$2.76K – 179
2025
Q2
$2.76K Hold
100
– – ﹤0.01% 164
2025
Q1
$2.84K Hold
100
– – ﹤0.01% 168
2024
Q4
$4.16K Hold
100
– – ﹤0.01% 171
2024
Q3
$6.68K Buy
+100
New +$9.18K ﹤0.01% 160
2024
Q1
– Sell
-50
Closed -$4.97K – 178
2023
Q4
$4.97K Buy
+50
New +$4.2K ﹤0.01% 161

Other funds holding MRNA

Syntax Research's MRNA Position: Q3 2026 in Review

Syntax Research opened a new position in Moderna (MRNA) in Q3 2026: 13 shares worth $2.5K. The stake represents ﹤0.01% of the portfolio and ranks #178 among its holdings. This is a return to the name: Syntax Research previously reported a position in MRNA as recently as Q2 2025.

Syntax Research first reported a position in MRNA in Q4 2023 and has held it in 6 quarters since. The position peaked at $6.68K in Q3 2024. 1,033 funds tracked by Wall St. Rank hold MRNA as of Q3 2026.

  • Syntax Research held 13 shares of Moderna worth $2.5K as of Q3 2026.
  • Moderna was a new Syntax Research position in Q3 2026.
  • Moderna made up ﹤0.01% of Syntax Research's portfolio in Q3 2026, its #178 holding.
  • Syntax Research first reported a position in Moderna in Q4 2023 and has held it in 6 quarters since.
  • Syntax Research's Moderna position peaked at $6.68K in Q3 2024.
  • 1,033 funds tracked by Wall St. Rank held Moderna as of Q3 2026.

Based on Syntax Research's 13F filing for Q3 2026, filed 4 Nov 2026.